Welcome to our dedicated page for Mediwound news (Ticker: MDWD), a resource for investors and traders seeking the latest updates and insights on Mediwound stock.
MediWound Ltd (Nasdaq: MDWD) is a biopharmaceutical innovator developing enzymatic therapeutics for non-surgical wound care. This page provides investors and healthcare professionals with essential updates on clinical advancements, regulatory milestones, and strategic developments.
Access consolidated information about NexoBrid adoption, EscharEx clinical trials, and pipeline progress. Stay informed about financial results, partnership announcements, and market expansion initiatives directly impacting MediWound's position in wound care innovation.
Key updates include FDA/EMA regulatory decisions, burn treatment protocols, chronic wound therapy breakthroughs, and peer-reviewed research findings. All content is verified through primary sources to ensure accuracy for investment and clinical decision-making.
Bookmark this page for streamlined access to MediWound's latest developments. Combine our updates with SEC filings and earnings call transcripts for comprehensive analysis of this enzymatic therapeutics leader.
MediWound Ltd. (Nasdaq: MDWD) announced that it will present updated clinical data from its EscharEx® Phase 2 trials at the 2023 Symposium on Advanced Wound Care (SAWC) Spring in National Harbor, Maryland, from April 26-30, 2023. Key opinion leaders will discuss current wound debridement practices and findings from the clinical studies during oral presentations on April 29, 2023. Two posters will present safety and efficacy results, showcasing EscharEx as a promising enzymatic solution for chronic wounds. CEO Ofer Gonen expressed confidence in EscharEx's potential as a leading treatment in the wound care market given its positive outcomes. The emphasis on EscharEx aligns with MediWound's commitment to advancing enzymatic solutions for tissue repair, with a Phase III study expected to commence in Q4 2023, highlighting its competitive advantages in the market.
MediWound Ltd. (NASDAQ: MDWD) reported total revenues of $26.5 million for 2022, a growth from $23.8 million in 2021, despite a 44% decrease in product revenue due to reduced BARDA procurement. The FDA approved NexoBrid in December 2022, leading to a $7.5 million milestone payment from Vericel. Operating loss improved to $8.3 million, down from $11.2 million in 2021. Cash position reached $66 million, supporting operations through 2026. EscharEx is set to enter Phase III trials in 2023, while launches in Japan and India are anticipated mid-2023.
MediWound Ltd. (Nasdaq: MDWD) has appointed Ms. Hani Luxenburg as Chief Financial Officer, effective May 14, 2023, succeeding Mr. Boaz Gur-Lavie, who will assist in the transition until July 31, 2023. Ms. Luxenburg brings over 20 years of experience in financial leadership, previously serving as CFO at BIRD Aerosystems and holding senior roles at AstraZeneca and Ernst & Young. She aims to support the U.S. launch of NexoBrid and oversee ongoing product development. CEO Ofer Gonen commended Gur-Lavie's contributions while expressing optimism for MediWound's growth under Ms. Luxenburg’s leadership.
MediWound Ltd. (NASDAQ: MDWD) has appointed Barry Wolfenson as Executive Vice President of Strategy and Corporate Development and Alicia Torrenova as Vice President of European Operations. Wolfenson brings over 20 years of leadership in wound care and regenerative medicine, previously co-founding vTail Healthcare Telecommunications and serving as a strategic advisor to Origin, Inc. Torrenova has managed operations across Spain, Portugal, and LATAM, significantly impacting product introductions for LifeCell. Both executives are expected to drive growth and innovation in MediWound's biotherapeutic solutions, including NexoBrid and EscharEx, enhancing the company’s competitive positioning.
FAQ
What is the current stock price of Mediwound (MDWD)?
What is the market cap of Mediwound (MDWD)?
